Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06273774
Other study ID # 8189-020
Secondary ID MK-8189-020
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 8, 2024
Est. completion date September 10, 2024

Study information

Verified date May 2024
Source Merck Sharp & Dohme LLC
Contact Toll Free Number
Phone 1-888-577-8839
Email Trialsites@merck.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to evaluate the safety and tolerability of MK-8189 in participants with stable bipolar I disorder. There will be no hypothesis testing in this study.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date September 10, 2024
Est. primary completion date September 10, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: The main inclusion criteria include but are not limited to the following: - Meets diagnostic criteria for bipolar I disorder, manic or mixed features according to the Diagnostic and statistical manual of Mental Disorders TR (DSM-5 TR) and considered to be in a non-acute phase of their illness. - History of receiving and tolerating antipsychotic medication within the usual dose range employed for bipolar I disorder. - Body mass index is 18 and 40 kg/m^2, inclusive. - If currently taking an antipsychotic, is able to discontinue it's use at least 5 days prior to study start and the duration of the study. Exclusion Criteria: The main exclusion criteria include but are not limited to the following: - Untreated or uncompensated endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases. - Evidence or history of a primary DSM-5 axis I psychiatric diagnosis other than those specified for inclusion. - History of cancer (malignancy). - Evidence or history of mental retardation, borderline personality disorder, or organic brain syndrome. - History of neuroleptic malignant syndrome or moderate to severe tardive dyskinesia. - Substance-induced psychotic disorder or behavioral disturbance. - DSM-5 TR defined substance use disorder within 3 months of screening. - History of seizure disorder beyond childhood or is receiving treatment with any anticonvulsant to prevent seizures. - Positive test(s) for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus. - Major surgery or donation/loss of 1 unit of blood within 4 weeks prior to screening. - Received any vaccine starting from 30 days prior to study intervention or is scheduled to receive any vaccine through 30 days following study intervention.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MK-8189
Oral Tablet
Placebo
Oral Tablet

Locations

Country Name City State
United States Atlanta Center for Medical Research ( Site 0001) Atlanta Georgia
United States Woodland International Research Group-Clinical Research ( Site 0009) Little Rock Arkansas
United States Hassman Research Institute Marlton Site ( Site 0006) Marlton New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experience One or More Adverse Events (AEs) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to ~28 days
Primary Number of Participants Who Discontinue Study Treatment Due to an AE An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to ~14 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Withdrawn NCT01495156 - Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Phase 4
Completed NCT00982020 - Study in Adolescents With Schizophrenia or Bipolar Disorder Phase 4
Completed NCT00746343 - Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study N/A
Completed NCT00177463 - L-Carnosine for Bipolar I Disorder N/A
Completed NCT03257865 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder Phase 3
Completed NCT03259555 - A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Phase 3
Not yet recruiting NCT06433635 - Sequential Multiple Assignment Randomized Trial for Bipolar Depression Phase 4
Completed NCT04127058 - Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia Phase 1
Recruiting NCT05977023 - NMDA Receptor Modulation for the Treatment of Bipolar I Disorder Phase 2
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Completed NCT03287869 - A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Participants With Bipolar I Disorder. Phase 3
Enrolling by invitation NCT04987229 - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects Phase 3
Completed NCT00761761 - Sensoril(Ashwaganhda)for Bipolar Disorder Phase 3
Completed NCT00232414 - A Double-Blind Randomized Placebo Controlled Study of Quetiapine for the Treatment of Depression in Adolescents With Bipolar Disorder Phase 3
Completed NCT03292848 - Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Phase 1
Active, not recruiting NCT04561622 - Emotional Proactive Processing in Bipolar Disorder
Recruiting NCT03943537 - Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders Phase 2
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Active, not recruiting NCT05658510 - Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) Phase 3